Literature DB >> 6980012

Review of long-term treatment with labetalol.

H J Waal-Manning, F O Simpson.   

Abstract

1 Labetalol has been used to treat 163 patients at the Dunedin Hypertension Clinic for periods up to 6.5 y, and of 128 patients in a New Zealand multicentre study for 2 yr. 2 Labetalol was often effective when other anti-hypertensive agents, including beta-blockers, had failed. It was usually given with a diuretic. 3 Mean daily dose was 700 mg (range 100-2400 mg). No tolerance to the anti-hypertensive effect was seen. 4 Some postural-induced decrease in blood pressure on labetalol was common. 5 Side-effects led to withdrawal of labetalol in about 25% of patients, mainly during the first few months of therapy. Another 25% had minor side-effects but could continue with the drug. 6 There were three types of side-effects (in order of frequency): (a) non-specific, (b) related to alpha-blockade and (c) related to beta-blockade. The latter were much less troublesome than on "pure" beta-blockers. 7 There was no significant evidence of renal haematological or hepatic toxicity. 8 Anti-nuclear antibody tests became positive on labetalol in about 15%, usually at low titres but in one patient the titre increased to a high level and fell when labetalol was stopped. 9 In a subset of 25 patients who took labetalol for the longest time (up to 6.5 yr) there was a 16% incidence of anti-mitochondrial antibodies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980012      PMCID: PMC1401832          DOI: 10.1111/j.1365-2125.1982.tb01891.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

Review 1.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

2.  A comparison of scalp tingling, thirst and polyuria in patients on labetalol and metoprolol.

Authors:  D M Coulter
Journal:  N Z Med J       Date:  1979-11-14

3.  Anti-mitochondrial antibodies associated with labetalol.

Authors:  J D Wilson; R J Booth; J Y Bullock; D G Campbell
Journal:  Lancet       Date:  1980-08-09       Impact factor: 79.321

4.  Treatment of hypertension with labetalol.

Authors:  P Bolli; H J Waal-Manning; F O Simpson; H M Seeman
Journal:  N Z Med J       Date:  1977-12-28

5.  Clinico-laboratory aspects of anti-nuclear and anti-native DNA antibody tests.

Authors:  J Webb
Journal:  Aust N Z J Med       Date:  1978

6.  Scalp tingling and difficulty in micturition in patients on labetalol.

Authors:  R R Bailey
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

7.  A five-year study of labetalol in hypertension.

Authors:  J Kane; I Gregg; M D Stephens
Journal:  Practitioner       Date:  1981-01

Review 8.  Antinuclear antibodies and cardiovascular drugs.

Authors:  J D Wilson
Journal:  Drugs       Date:  1980-04       Impact factor: 9.546

  8 in total
  4 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

2.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 3.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 4.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.